SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against GenVec, Inc.

WILMINGTON, Del., April 17, 2017 -- Rigrodsky & Long, P.A.:

Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of GenVec, Inc. (“GenVec”) (NASDAQ:GNVC) common stock in connection with the proposed acquisition of GenVec by Intrexon Corporation and Intrexon GV Holding, Inc. (collectively, “Intrexon”) announced on January 24, 2017 (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against GenVec, its Board of Directors (the “Board”), and Intrexon, is captioned Parshall v. GenVec, Inc., Case No. 1:17-cv-00338-GMS (D. Del.).

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail at [email protected]; or at http://rigrodskylong.com/contact-us/. 

On January 24, 2017, GenVec entered into an agreement and plan of merger (the “Merger Agreement”) with Intrexon.  Pursuant to the Merger Agreement, GenVec shareholders will receive 0.297 shares of Intrexon common stock, plus one contingent payment right (the “Proposed Transaction”).

Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a registration statement (the “Registration Statement”) filed with the United States Securities and Exchange Commission on March 17, 2017.  The Registration Statement, which recommends that GenVec stockholders vote in favor of the Proposed Transaction, omits material information necessary to enable shareholders to make an informed decision as to how to vote on the Proposed Transaction, including material information with respect to GenVec’s financial projections, the analyses performed by GenVec’s financial advisor, and potential conflicts of interest.  The Complaint seeks injunctive and equitable relief and damages on behalf of holders of GenVec common stock. 

If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2017.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:                                                                                             

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
[email protected] 
http://www.rigrodskylong.com